Clinical trials: Multiple System Atrophy (MSA)
Multiple System Atrophy - Parkinsonian Subtype (MSA-P), Multiple System Atrophy, MSA
The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy
This is a single-center, prospective, randomized, open-label, blinded outcome assessment (PROBE) study. At the end of the PROBE study, patients who have completed the study may opt to enter the open-label extension (OLE) study.
- Trial name
- SPRITE (NCT06765733)
- Testing
- Aleeto
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tiantan Hospital
Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy
A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa
The purpose of this study is to see whether droxidopa is effective in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy…
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
- Trial name
- NOH301 (NCT00782340)
- Testing
- Droxidopa
- Where
- 21 sites in United States, Canada
- Volunteers
- 263 people
- Sponsor
- Chelsea Therapeutics
Multiple System Atrophy
Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA
Evaluate the effects of L-Threo DOPS on orthostatic hypotension symptoms and other non-motor symptoms in patients with Multiple System Atrophy (MSA) after 12 weeks following randomization to continued therapy with droxidopa or…
- Trial name
- DOPS-AMS (NCT02071459)
- Testing
- L-Threo DOPS
- Where
- 13 sites in France
- Volunteers
- 107 people
- Sponsor
- University Hospital, Toulouse
Multiple System Atrophy
Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA)
This trial will the efficacy of KM-819 compared to placebo in subjects with MSA for slowing the progression of MSA.
- Trial name
- NCT05695378
- Testing
- KM-819
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Kainos Medicine Inc.
Multi-system Atrophy - Parkinsonian Type, Orthostatic Hypotension, Dysautonomic
Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease.
This study is aimed at patients with multi-system atrophy - parkinsonian type (P-MSA) or Parkinson's disease (PD) receiving dopaminergic drugs and suffering from orthostatic hypotension (OH).
- Conditions
- Multi-system Atrophy - Parkinsonian Type, Orthostatic Hypotension, Dysautonomic, Parkinson Disease
- Trial name
- CARBIDOH (NCT06831500)
- Testing
- Administration of Carbidopa/levodopa
- Where
- 2 sites in Switzerland
- Volunteers
- 36 people
- Sponsor
- Julien Bally
Parkinson Disease, Dementia With Lewy Bodies
[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
Study goal: The goal of this prospective head to head comparison is to evaluate the effectiveness of [18F]-MFBG PET in assessing cardiac innervation, comparing it with [123I]-MIBG SPECT The study's primary focus is on…
- Conditions
- Parkinson Disease, Dementia With Lewy Bodies, MSA - Multiple System Atrophy, Alzheimer Disease
- Trial name
- NCT06120049
- Testing
- [18F]-MFBG PET CT, [18F]-FE-PE2I PET CT or PET MRI, [123I]-MIBG SPECT CT
- Where
- 2 sites in Belgium
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- prof. dr. Koen Van Laere
Symptomatic Neurogenic Orthostatic Hypotension
Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3 study to evaluate efficacy, safety, and tolerability of ampreloxetine (TD-9855) in subjects with primary autonomic failures (MSA, PD, or PAF) and symptomatic nOH with up to 4 weeks of treatment.
- Trial name
- SEQUOIA (NCT03750552)
- Testing
- ampreloxetine
- Where
- 125 sites in United States, Australia and 17 more
- Volunteers
- 195 people
- Sponsor
- Theravance Biopharma
MSA - Multiple System Atrophy, MSA
Autologous Stem Cell Therapy in Patients With Multiple System Atrophy
This study investigates the safety and efficacy of autologous stem cell therapy in patients with Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism…
- Trial name
- NCT07465198
- Testing
- MSCs
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Biocells Medical
MSA - Multiple System Atrophy
MotIoN aDaptive Deep Brain Stimulation for MSA
Patients routinely undergo deep brain stimulation (DBS) for treatment of symptoms related to neurodegenerative conditions, most commonly Parkinson's disease.
- Trial name
- MINDS (NCT05197816)
- Testing
- Deep brain stimulation
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- University of Oxford
Parkinson's Disease (PD), Multiple System Atrophy (MSA)
[18F]ACI-15916 PET in α-synucleinopathies
The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein α-synuclein [involved in some diseases such as Parkinson's disease, Lewy body dementia and Multiple…
- Conditions
- Parkinson's Disease (PD), Multiple System Atrophy (MSA), Dementia With Lewy Bodies (DLB)
- Trial name
- NCT06891703
- Testing
- [18F]ACI-15916
- Where
- Sweden
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
Atypical Parkinsonism, MSA - Multiple System Atrophy
Integrated Management of Atypical Parkinsonism: A Home-based Patient-Centered Healthcare Delivery Based on Telenursing (IMPACT Study)
This project aims to investigate whether an integrated model based on proactive and reactive telenursing monitoring coordinated by a parkinsonism nurse specialist (case manager) is able to improve care delivery and quality of…
- Conditions
- Atypical Parkinsonism, MSA - Multiple System Atrophy, PSP, Nurse-Patient Relations
- Trial name
- NCT05792332
- Testing
- Telemonitoring, Standard-of-care
- Where
- 4 sites in Italy
- Volunteers
- 164 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Symptomatic Neurogenic Orthostatic Hypotension (NOH), Parkinson's Disease
Fipamezole in Neurogenic Orthostatic Hypotension
The purpose of this study is to determine whether Fipamezole is effective in the treatment of orthostatic hypotension and related symptoms in multiple system atrophy and Parkinson's disease.
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension (NOH), Parkinson's Disease, Multiple System Atrophy
- Trial name
- Foehn (NCT00758849)
- Testing
- Fipamezole
- Where
- 4 sites in France, Portugal
- Volunteers
- 24 people
- Sponsor
- Juvantia Pharma Ltd
Symptomatic Neurogenic Orthostatic Hypotension, MSA
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of ampreloxetine in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension, MSA, Parkinson's Disease (PD), Pure Autonomic Failure (PAF)
- Trial name
- REDWOOD (NCT03829657)
- Testing
- ampreloxetine
- Where
- 82 sites in United States, Australia and 17 more
- Volunteers
- 203 people
- Sponsor
- Theravance Biopharma